Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Simvastatin

FDA-approved product (tablet, oral), marketed as Flolipid, Simvastatin, Zocor.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Simvastatin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Abnormal circulating lipid concentration
  • Acute myocardial infarction
  • Cardiovascular disease
  • Coronary artery disease
  • Familial hypercholesterolemia
  • Hypercholesterolemia
  • Hyperlipidemia
  • Myocardial infarction
  • Stroke

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Hmg coa reductase inhibitors
FDA pharmacologic class
HMG-CoA Reductase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli36.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis42.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Simvastatin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Simvastatin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • StAtins in Frail OldEr Patients with Ischemic Stroke or Transient Ischemic Attack - the Randomized Controlled Trial

    NCT06785727 · start 2025-02-01

    Registered record
    Registry ID
    NCT06785727
    Conditions
    Ischemic Stroke; Transient Ischemic Attack
    Interventions
    Statin (atorvastatin, fluvastatin, pravastatin, rosuvastatin or simvastatin)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2025-02-01
    Completion
    2029-07-01
    Enrolment
    612

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIschemic Stroke; Transient Ischemic Attack
    InterventionStatin (atorvastatin, fluvastatin, pravastatin, rosuvastatin or simvastatin)
    PhasePhase 4
    Registry statusNot yet recruiting

  • Effect of Locally Applied Simvastatin Gel on Dental Implant Stability and Marginal Bone Level

    NCT07194447 · start 2024-10-03

    Registered record
    Registry ID
    NCT07194447
    Conditions
    Dental Implants , Osseointegration , Marginal Bone Loss , Implant Stability
    Interventions
    Simvastatin Gel; Methylcellulose Gel
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2024-10-03
    Completion
    2025-07-06
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDental Implants , Osseointegration , Marginal Bone Loss , Implant Stability
    InterventionSimvastatin Gel; Methylcellulose Gel
    PhaseNot applicable
    Registry statusCompleted

  • Drug-Drug Interaction (DDI) Study of Leramistat in Healthy Adult Subjects

    NCT06379958 · start 2024-04-08

    Registered record
    Registry ID
    NCT06379958
    Conditions
    Pharmacokinetics
    Interventions
    leramistat 40mg; Itraconazole 200 mg; Phenytoin 100 Mg Oral Capsule; Simvastatin 40mg; Upadacitinib 15 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2024-04-08
    Completion
    2024-09-30
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPharmacokinetics
    Interventionleramistat 40mg; Itraconazole 200 mg; Phenytoin 100 Mg Oral Capsule; Simvastatin 40mg +1 more
    PhasePhase 1
    Registry statusUnknown

  • Clinical Evaluation of Simcyp-Guided Simvastatin Dosing in Patients With Liver Cirrhosis

    NCT07459972 · start 2024-03-15

    Registered record
    Registry ID
    NCT07459972
    Conditions
    Liver Cirrhosis; Portal Hypertension Related to Cirrhosis
    Interventions
    Simvastatin 15 mg; Simvastatin 5 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2024-03-15
    Completion
    2025-06-15
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Cirrhosis; Portal Hypertension Related to Cirrhosis
    InterventionSimvastatin 15 mg; Simvastatin 5 mg
    PhasePhase 4
    Registry statusCompleted

  • Osteogenic Action of a Biphasic Bioceramic With Statin in a Third Molar Extraction Model

    NCT06338241 · start 2024-03-02

    Registered record
    Registry ID
    NCT06338241
    Conditions
    Bone Loss; Regenerative Inflammation
    Interventions
    Biphasic bioceramic of tricalcium phosphate and hydroxyapatite with simvastatin; Bovine Hydroxyapatite
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2024-03-02
    Completion
    2025-09-02
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBone Loss; Regenerative Inflammation
    InterventionBiphasic bioceramic of tricalcium phosphate and hydroxyapatite with simvastatin; Bovine Hydroxyapatite
    PhasePhase 4
    Registry statusUnknown

  • Effect of Repeated Oral Doses of Avacopan on the Pharmacokinetics (PK) of a Single Dose of Simvastatin

    NCT06207682 · start 2022-06-28

    Registered record
    Registry ID
    NCT06207682
    Conditions
    Healthy Volunteers
    Interventions
    Avacopan; Simvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-06-28
    Completion
    2022-08-11
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionAvacopan; Simvastatin
    PhasePhase 1
    Registry statusCompleted

  • Improving Blood Lipid Management in Symptomatic Intracranial Atherosclerotic Stenosis on Clinical Outcome

    NCT05397405 · start 2022-05-23

    Registered record
    Registry ID
    NCT05397405
    Conditions
    Intracranial Artery Stenosis
    Interventions
    PCSK9 inhibitor
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2022-05-23
    Completion
    2026-05-01
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntracranial Artery Stenosis
    InterventionPCSK9 inhibitor
    PhaseNot applicable
    Registry statusRecruiting

  • Statin and Bone Health

    NCT05613400 · start 2022-04-13

    Registered record
    Registry ID
    NCT05613400
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    Simvastatin 10mg; Ezetimibe 10mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2022-04-13
    Completion
    2025-06-30
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionSimvastatin 10mg; Ezetimibe 10mg
    PhasePhase 4
    Registry statusUnknown

  • A Study to Evaluate the DDI of DBPR108 With Metformin,Glibenclamide,Valsartan, or Simvastatin in Healthy Subjects

    NCT04859452 · start 2021-05-26

    Registered record
    Registry ID
    NCT04859452
    Conditions
    Healthy Subjects
    Interventions
    DBPR108 tablets; Metformin hydrochloride tablets; Glibenclamide tablets; Valsartan Capsules; Simvastatin tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-05-26
    Completion
    2021-07-09
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subjects
    InterventionDBPR108 tablets; Metformin hydrochloride tablets; Glibenclamide tablets; Valsartan Capsules +1 more
    PhasePhase 1
    Registry statusCompleted

  • Effect of Local Application of Simvastatin Versus Bone Powder on Implant Bone Changes

    NCT06016218 · start 2021-01-05

    Registered record
    Registry ID
    NCT06016218
    Conditions
    Dental Caries Extending to Pulp; Dental Implant Failed
    Interventions
    Simvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2021-01-05
    Completion
    2023-02-05
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDental Caries Extending to Pulp; Dental Implant Failed
    InterventionSimvastatin
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Efficacy of the Combination of Simvastatin Plus Rifaximin in Patients With Decompensated Cirrhosis to Prevent ACLF Development

    NCT03780673 · start 2019-01-03

    Registered record
    Registry ID
    NCT03780673
    Conditions
    Liver Cirrhoses
    Interventions
    Simvastatin; Rifaximin; Placebo of Simvastatin; Placebo of Rifaximin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2019-01-03
    Completion
    2022-12-01
    Enrolment
    254

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Cirrhoses
    InterventionSimvastatin; Rifaximin; Placebo of Simvastatin; Placebo of Rifaximin
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • 7T Magnetic Resonance Spectroscopy and Skeletal Muscle Biopsy Findings in Statin Associated Adverse Muscle Events

    NCT04507373 · start 2018-08-17

    Registered record
    Registry ID
    NCT04507373
    Conditions
    Muscle Cramp; Ache; Weakness, Muscle; Statin Adverse Reaction
    Interventions
    Simvastatin 40mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2018-08-17
    Completion
    2021-12-20
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMuscle Cramp; Ache; Weakness, Muscle; Statin Adverse Reaction
    InterventionSimvastatin 40mg
    PhasePhase 4
    Registry statusTerminated

  • Drug-Drug Interaction Study of Vadadustat With Rosuvastatin, Sulfasalazine, Pravastatin, Atorvastatin and Simvastatin

    NCT03801733 · start 2018-06-17

    Registered record
    Registry ID
    NCT03801733
    Conditions
    Drug Interaction Potentiation
    Interventions
    Vadadustat; Simvastatin; Rosuvastatin; Atorvastatin; Pravastatin; Sulfasalazine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-06-17
    Completion
    2018-11-24
    Enrolment
    134

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Interaction Potentiation
    InterventionVadadustat; Simvastatin; Rosuvastatin; Atorvastatin +2 more
    PhasePhase 1
    Registry statusCompleted

  • Simvastatin in the Prevention of Recurrent Pancreatitis

    NCT04021498 · start 2017-09-29

    Registered record
    Registry ID
    NCT04021498
    Conditions
    Pancreatitis Relapsing
    Interventions
    Simvastatin 40mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2017-09-29
    Completion
    2025-03-01
    Enrolment
    83

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatitis Relapsing
    InterventionSimvastatin 40mg; Placebo
    PhasePhase 3
    Registry statusTerminated

  • Simvastatin Plus Rifaximin in Decompensated Cirrhosis

    NCT03150459 · start 2017-07-26

    Registered record
    Registry ID
    NCT03150459
    Conditions
    Cirrhoses, Liver
    Interventions
    Simvastatin 20 mg; Simvastatin 40mg; Rifaximin 400 mg; Placebo of Simvastatin; Placebo of Rifaximin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-07-26
    Completion
    2018-03-12
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCirrhoses, Liver
    InterventionSimvastatin 20 mg; Simvastatin 40mg; Rifaximin 400 mg; Placebo of Simvastatin +1 more
    PhasePhase 2
    Registry statusCompleted